JW Therapeutics (JW (Cayman) Therapeutics Co. Ltd) filed its monthly return for the period ended 31 May 2026, confirming that no changes occurred in either authorised or issued share capital during the month.

• Share capital stability – Authorised share capital stood at 5 billion ordinary shares with a par value of USD 0.00001, equivalent to USD 50,000. – Issued ordinary shares remained at 416.73 million; the company held no treasury shares.

• Public-float compliance The company affirmed that it continued to meet the Main Board’s 25% minimum public-float requirement as of 31 May 2026.

• Equity incentive landscape – Share option schemes: 23.07 million options were outstanding, unchanged from the previous month. • During May, the company granted 2.00 million new options under its Post-IPO Incentivization Scheme at an exercise price of HKD 2.32 (grant date: 19 May 2026). • No options were exercised or cancelled. – Restricted Share Units: Up to 1.20 million shares may be issued under the 2019 RSU scheme; no RSUs were granted or vested in May.

• Potential dilution If all outstanding options and RSUs were exercised or vested, up to 24.27 million new shares could be issued, representing approximately 5.82% of the current issued share base.

• No other equity instruments The company reported no warrants, convertibles, share repurchases, or other share-related movements during the month.

The filing was authorised by Executive Director Feng Tian and submitted on 3 June 2026.